Devices/drugs to remain under DG Sanco in newly approved EU Commission
This article was originally published in Clinica
Oversight of medical device and drug policy in the EU is to remain with the European Commission’s health directorate (DG Sanco), and not with the industry directorate (DG ENTR). The news was announced just before the European Parliament today voted in favor of the new European Commission, which will be led by President Jean-Claude Juncker and officially begin work on 1 November. There were 423 votes for the new commission and its new college of commissioners, 209 votes against and 67 abstentions.
You may also be interested in...
Eighteen years of free trade threatens to come to a sudden stop, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
With just a few months remaining until the full application of the EU Medical Device Regulation, notified body designations are still only trickling through. Ireland is the latest EU member state to have a resident MDR notified body.